Immutep Limited Class Action Lawsuit – IMMP

According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating false and misleading statements and/or concealing material adverse facts concerning the efficacy and safety of its TACTI-004 Phase III clinical trial study.

On March 13, 2026, Immutep issued a press release announcing that the Independent Data Monitoring (IDMC) for the TACTI-004 Phase III study recommended that the trial be discontinued following a planned interim futility analysis. Further, based on its review of the available safety and efficacy data, the IDMC recommended that the trial be discontinued for futility.

Following this news, the price of Immutep’s ADRs declined dramatically. From a closing market price of $2.76 per share on March 12, 2026, Immutep’s stock price fell to $0.48 per share on March 13, 2026, a decline of about 83%.